EMERGENT PRODUCT DEVELOPMENT GERMANY GMBH
United Kingdom
Manufacturer/ Producer
Emergent BioSolutions is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics, which are a subset of products that are known as biologics. Immunobiotics are biologics that induce or assist the body? s immune system to prevent or treat disease, consisting of vaccines and certain therapeutic products, including immune globulins. We operate in two business segments: biodefense and commercial. In our biodefense business, we develop, manufacture and commercialize immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. In our commercial business, we develop immunobiotics for use against infectious disease. Our commercial immunobiotic product candidates are designed to address significant unmet or underserved public health needs.
Website
Manufacturer/ Producer
17 Walter-Gropius-Str.
80807 München - United Kingdom
Company info
Key figures
-
- Company headcount
- 1 – 10
Organisation
-
- Year established
- 2003
-
- Main activity
- Manufacturer/ Producer
Activities of EMERGENT PRODUCT DEVELOPMENT GERMANY GMBH
- Medical and surgical instruments
- Pharmaceutical products
- Biodefense Products
- Commercial Products
europages also recommends
A selection of companies related to the activity:
A selection of products that might interest you
MPS MICRO PRECISION SYSTEMS AG
Switzerland
Novostia, a Swiss startup founded in 2017, has entrusted MPS with the manufacture of its TRIFLO artificial valve, a revolutionary aortic prosthesis on several levels. Thanks to its aerodynamic design, the presence of three leaflets and the absence of physical pivot axes for the leaflets, the TRIFLO valve aims to satisfy the following three criteria: - A device lifespan at least equal to that of the patient, to avoid the need for a second surgical procedure. This means more than 30 million flap openings and closures per year, with no leaks, blockages, cracks, ruptures or flap escapes. - The artificial valve must not lead to thrombosis, so that patients do not need to take anticoagulants. - Operation (flap opening and closing, blood flow through the valve) must be as silent as possible, so as not to disturb the patient or those around him, day or night. The TRIFLO device is in clinical trial and is not approved for sale.
Request for quotes
Create one request and get multiple quotes form verified suppliers.
- Only relevant suppliers
- Data privacy compliant
- 100% free